AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice

Diabetic nephropathy (DN) is a major cause of end-stage kidney disease, where TGF-β1/Smad signaling plays an important role in the disease progression. Our previous studies demonstrated a combination of Traditional Chinese Medicine derived Smad7 agonist Asiatic Acid (AA) and Smad3 inhibitor Naringenin (NG), AANG, effectively suppressed the progression of renal fibrosis in vivo. However, its implication in type-2 diabetic nephropathy (T2DN) is still unexplored. Here, we detected progressive activation of Smad3 but reduction of Smad7 in db/db mice during T2DN development. Therefore, we optimized the dosage and the combination ratio of AANG to achieve a better rebalancing Smad3/Smad7 signaling for treatment of T2DN. Unexpectedly, preventive treatment with combined AANG from week 4 before the development of diabetes and T2DN effectively protected against the onset of T2DN. In contract, these inhibitory effects were lost when db/db mice received the late AANG treatment from 12-24 weeks. Surprisingly, preventive treatment with AANG ameliorated not only T2DN but also the primary disease type-2 diabetes (T2D) with relative normal levels of fasting blood glucose and HbA1c, and largely improving metabolic abnormalities especially on insulin insensitivity and glucose tolerance in db/db mice. Mechanistically, AANG effectively prevented both Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation in the diabetic kidney in vivo and advanced glycation end-products (AGE) stimulated tubular epithelial mTEC cells in vitro. More importantly, we uncovered that preventive treatment with AANG effectively protected against diabetic-associated islet injury via restoring the β cell development in db/db mice. Taken together, we discovered that the early treatment with combined AANG can effectively protect against the development of T2D and T2DN via mechanism associated with protection against Smad3-depenedent islet injury.

[1]  Xiao-ming Meng,et al.  AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF‐β/Smad signalling in hepatocellular carcinoma , 2021, Journal of cellular and molecular medicine.

[2]  Tin-Lap Lee,et al.  Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage–myofibroblast transition , 2020, Proceedings of the National Academy of Sciences.

[3]  Tin-Lap Lee,et al.  The Mincle/Syk/NF-κB Signaling Circuit Is Essential for Maintaining the Protumoral Activities of Tumor-Associated Macrophages , 2020, Cancer Immunology Research.

[4]  Ying-ying Zhang,et al.  The Emerging Role of Innate Immunity in Chronic Kidney Diseases , 2020, International journal of molecular sciences.

[5]  Ying-ying Zhang,et al.  LRNA9884, a Novel Smad3-Dependent Long Noncoding RNA, Promotes Diabetic Kidney Injury in db/db Mice via Enhancing MCP-1–Dependent Renal Inflammation , 2019, Diabetes.

[6]  H. Lan,et al.  The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population , 2018, Immunity & Ageing.

[7]  H. Lan,et al.  Combination of Asiatic Acid and Naringenin Modulates NK Cell Anti-cancer Immunity by Rebalancing Smad3/Smad7 Signaling. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  W. Lam,et al.  Majority of Chinese Medicine Herb Category “Qing Re Yao” Have Multiple Mechanisms of Anti-inflammatory Activity , 2018, Scientific Reports.

[9]  K. To,et al.  A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro. , 2018, Journal of visualized experiments : JoVE.

[10]  H. Lan,et al.  Novel lncRNA Erbb4-IR Promotes Diabetic Kidney Injury in db/db Mice by Targeting miR-29b , 2017, Diabetes.

[11]  Xiao-ming Meng,et al.  Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development , 2017, Nature Communications.

[12]  H. Lan,et al.  C-Reactive Protein Promotes Diabetic Kidney Disease in db/db Mice via the CD32b-Smad3-mTOR signaling Pathway , 2016, Scientific Reports.

[13]  Xiao-ming Meng,et al.  TGF-β/Smad3 signalling regulates the transition of bone marrow-derived macrophages into myofibroblasts during tissue fibrosis , 2015, Oncotarget.

[14]  Xiao-ming Meng,et al.  Treatment of renal fibrosis by rebalancing TGF-β/Smad signaling with the combination of asiatic acid and naringenin , 2015, Oncotarget.

[15]  Robert R. Henry,et al.  Type 2 diabetes mellitus , 2015, Nature Reviews Disease Primers.

[16]  Xiao-Fan Wang,et al.  Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice , 2015, Circulation. Heart failure.

[17]  Xueqing Yu,et al.  Long Noncoding RNA Arid2-IR Is a Novel Therapeutic Target for Renal Inflammation. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Xiao-ming Meng,et al.  MicroRNA-29b inhibits diabetic nephropathy in db/db mice. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  S. Kahn,et al.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future , 2014, The Lancet.

[20]  H. Lan,et al.  Chaihuang-Yishen Granule Inhibits Diabetic Kidney Disease in Rats through Blocking TGF-β/Smad3 Signaling , 2014, PloS one.

[21]  K. Prasadan,et al.  A Smad Signaling Network Regulates Islet Cell Proliferation , 2013, Diabetes.

[22]  Qiuyue Wang,et al.  Levels of Inflammatory Cytokines in Type 2 Diabetes Patients with Different Urinary Albumin Excretion Rates and Their Correlation with Clinical Variables , 2013, Journal of diabetes research.

[23]  Y. Li,et al.  Disruption of Smad7 Promotes ANG II-Mediated Renal Inflammation and Fibrosis via Sp1-TGF-β/Smad3-NF.κB-Dependent Mechanisms in Mice , 2013, PloS one.

[24]  A. Olokoba,et al.  Type 2 diabetes mellitus: a review of current trends. , 2012, Oman medical journal.

[25]  P. Sun,et al.  Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. , 2011, Cell metabolism.

[26]  H. Lan,et al.  The Protective Role of Smad7 in Diabetic Kidney Disease: Mechanism and Therapeutic Potential , 2011, Diabetes.

[27]  F. Burczynski,et al.  Attenuation of Diabetic Nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) Rats with a Combination of Chinese Herbs (Tangshen Formula) , 2011, Evidence-based complementary and alternative medicine : eCAM.

[28]  H. Lan,et al.  The Protective Role of Smad 7 in Diabetic Kidney Disease : Mechanism and Therapeutic Potential , 2011 .

[29]  Hong-Jian Zhu,et al.  Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. , 2003, Kidney international.

[30]  A. E. El Nahas,et al.  Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.